LSBCF (LakeShore Biopharma Co) Selling and Marketing Expense: $35.60 Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is LakeShore Biopharma Co Selling and Marketing Expense?

LakeShore Biopharma Co LSBCF Selling and Marketing Expense is $35.60 Mil as of Mar. 2025.

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. LakeShore Biopharma Co's Selling and Marketing Expense for the six months ended in Mar. 2025 was $16.23 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2025 was $35.60 Mil.

LakeShore Biopharma Co Selling and Marketing Expense Related Terms

LakeShore Biopharma Co Selling and Marketing Expense Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Selling and Marketing Expense Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Selling and Marketing Expense
10.67 26.12 36.51 38.94 35.14

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only 14.71 21.61 17.04 19.38 16.23

LakeShore Biopharma Co Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $35.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling and Marketing Expense of $35.60 Mil mean?
LakeShore Biopharma Co (LSBCF) has a Selling and Marketing Expense of $35.60 Mil as of Mar. 2025. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Selling and Marketing Expense too high?
LakeShore Biopharma Co's current Selling and Marketing Expense is $35.60 Mil.
How does LakeShore Biopharma Co's Selling and Marketing Expense compare to ACUT and PPCB?
LakeShore Biopharma Co's Selling and Marketing Expense of $35.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling and Marketing Expense for a Biotechnology company?
A good Selling and Marketing Expense depends on the Biotechnology industry context. However, Selling and Marketing Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling and Marketing Expense mean?
A high Selling and Marketing Expense can signal that a stock is expensive relative to its fundamentals. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Selling and Marketing Expense is $35.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Selling and Marketing Expense of $35.60 Mil. The current Selling and Marketing Expense is $35.60 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling and Marketing Expense calculated?
Selling and Marketing Expense is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Selling and Marketing Expense is $35.60 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.